source
- Merck R&D chief says company has outpaced rivals with its sac-TMT cancer platformDean Li, the head of Merck Research Laboratories, said the company believes its sac-TMT cancer program gives it a competitive edge over other firms developing next-generation oncology therapies. T…
- UK secures £500m biopharma investment as Vertex commits over £300m to new Oxford R&D hub, while Teva plans New Jersey plant closureThe UK government’s autumn budget has attracted about £500 million in new biopharma commitments, signalling strong support for the sector. Vertex Pharmaceuticals disclosed that it will put more th…